Market Overview

Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Share:
Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were trading higher Tuesday after Eylea, its product to treat retinal conditions, snagged another approval.

What Happened

Regeneron said Tuesday ahead of the market open that the FDA approved the Chemistry, Manufacturing and Controls Prior Approval Supplement, or PAS, for the Eylea prefilled syringe.

Eylea, a vascular endothelial growth factor, is already approved four retinal conditions: neovascular wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.

The first approval came through in 2011.

Why It's Important

The 2mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer Eylea, requiring fewer preparatory steps compared to vials, Regeneron said.

"This approval may help doctors more conveniently and efficiently deliver EYLEA to appropriate patients," Chief Scientific Officer George Yancopoulos said in a statement. 

The company said the Eylea prefilled syringe is likely to be made available to physicians and patients this year.

Regeron shares were trading 2.57% higher to $303.47 at the time of publication Tuesday. 

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

Posted-In: EYLEABiotech News FDA Trading Ideas Best of Benzinga

 

Related Articles (REGN)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis